I-Ribavirin iDrug kunye neNyango ye-Hepatitis C

Agent Ativiral Agent

I-Ribavirin iyisisigciwane esinamandla esinamandla sokusebenzisa isifo se- hepatitis C. Ayiqondi kakuhle indlela i-ribavirin kodwa, kodwa ngokubanzi, iphazamisa intsholongwane 'yokuphindaphinda. I-Ribavirin ivunyiwe yi-Food and Drug Administration (FDA) yokunyanga kwe-hepatitis C kwaye kuluhlu lwe-World Health Organisation List of Medicine Essential.

I-Ribavirin idayiswa ngaphantsi kweenombolo zamagama ezigama, kuquka uCopegus, Rebetol, Ribasphere kunye neRibaPak.

Ukusetyenziswa kweziyobisi

Ngaphambi kokusungulwa kwee-anti-viral (DAAs) ngokukhawuleza ngo-2013-ezibandakanya iziyobisi zikaSovaldi , iHarvoni , iDadlinza kunye ne- Viekira Pak , phakathi kwabanye-indlela efanelekileyo kakhulu yokunyanga i-hepatitis C yayikunye kunye ne-ribavirin kunye ne- peginterferon . Ulwaphulo oluninzi luyaziwa ngokuba negalelo eliphezulu lemiphumo yonyango, ezinye zazo ezinokuba zinzulu. Sekunjalo, ulwalamano oluhlangeneyo lukwazi ukuphumeza impendulo eqhubekayo ye-virologic (inkcazo yeklinikhi yokunyanga) malunga nama-50% amacala.

Namhlanje, kunye ne-DAA entsha yeklasi, ukusetyenziswa kwe-ribavirin kuye kwehla nangona kunjalo kusebekiwe kwimibandela ethile yokwelapha, ngokukodwa ngeengxaki ezithile zofuzo (i- genotype ) yegciwane kunye nezigulane ezinezonyango ezingaphumelelanga ngaphambili kunye / okanye isifo esiqhambileyo sesibindi.

Ulawulo Lweziyobisi

I-Ribavirin ithathwa ngomlomo, ngokuqhelekileyo kumathamo amabini athatywe iiyure ezili-12. Isilinganiselo esilinganiselweyo ukusuka ku-800 mg ukuya kwi-1,400 mg ngosuku. Ugqirha wakho uya kugqiba ukuba i-ribavirin ingayichaza kangakanani i-genotype yesifo sakho, isisindo sakho, kunye naziphi ezinye iziyobisi eziza kulawulwa kwonyango.

Imiphumo Yecala Lonyango

Imiphumo emibi ye-ribavirin iyahluka ukusuka kumntu ukuya kumntu, kunye nabanye abantu abalawulayo baya kuba neziganeko ezibi kakhulu xa abanye beva iimpawu abazijonga bengenakuzithengiswa. Iziphumo eziqhelekileyo ezichaphazelekayo nokusetyenziswa kwe-peginterferon zi:

Izigulane zonyango ziza kuthethwa ngeRuba Rage, ezifaniswa ukungaxhatshazi ngokubanzi kunye nokuphazamiseka ngokukhawuleza. Nangona eli gama libonisa imbangela yi-ribavirin, ngokuqhelekileyo idibene ne-peginterferon. Ngandlela-thile i-Anti-depressants imiselwe ukuba ilawule le meko, ingakumbi kwizigulane ezineengxaki ze-psychiatry zangaphambili.

Iindleko zonyango kunye nokuFikelela

Inkqubo epheleleyo yeyeza e-ribavirin inokuba yindleko kodwa, ngenhlanhla, nge-DAA entsha yeklasi, ubude bonyango bufutshane kakhulu kunaphambili. Kwixesha elidlulileyo, lingadala kwi-12,000 yeedola kwikhosi epheleleyo. Namhlanje, kulindeleke ukuba ixabise ngaphezu kwe-$ 2,500 kwiikhosi zeeveki ezili-12 kunye ne-$ 5,000 kwiikhosi ezili-16.

I-Medicaid, i-Medicare, kunye ne-inshurensi yabucala iza kubandakanya iindleko ze-interferon xa unyango lwe-hepatitis C luvunyiwe.

Ukuhlawulwa kwe-Co-pay can be searched by the manufacturer of drugs for patient patients, kwakunye neenkqubo zokuncedisa isigulane (PAPs) kwizigulane ezingafumanekiyo okanye ezingenayo imali.

Iingqinisiso zonyango

I-Ribavirin ithathwa njengekhuselekile kuninzi lwabantu, kodwa kukho abantu abathile unyango luphikisana. I-Ribavirin kufuneka igwenywe kwiimeko ezilandelayo:

Njalo qiniseka ukuba ugqirha wakho unembali yakho epheleleyo yonyango, kuquka ulwazi malunga naluphi na olunye unyango olungapheliyo unakho (umzekelo, i- HIV , isifo sikashukela) okanye naziphi na izicwangciso onokufuneka uzikhulelwe.

Imithombo:

Genentech. "I-Copegus: eziphambili zeNgcaciso yoLwazi." Ufikelele kwiDisemba 31, 2015.

Merck. "I-Rebetol: eziphambili ze-Information Information." Ufikelele kwiDisemba 31, 2015.